pH levels drive bacterial community structure in sediments of the Qiantang River as determined by 454 pyrosequencing

por Liu, Shuai, Ren, Hongxing, Shen, Lidong, Lou, Liping, Tian, Guangming, Zheng, Ping, Hu, Baolan
Publicado 2015

Eco-Stoichiometric Alterations in Paddy Soil Ecosystem Driven by Phosphorus Application

por Li, Xia, Wang, Hang, Gan, ShaoHua, Jiang, DaQian, Tian, GuangMing, Zhang, ZhiJian
Publicado 2013

Correction: Eco-Stoichiometric Alterations in Paddy Soil Ecosystem Driven by Phosphorus Application

por Li, Xia, Wang, Hang, Gan, ShaoHua, Jiang, DaQian, Tian, GuangMing, Zhang, ZhiJian
Publicado 2013

Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer

por Zhang, Jie, Hong, Yang, Wang, Liang, Hu, Weiheng, Tian, Guangming, Wu, Di, Wang, Yang, Dai, Ling, Zhang, Ziran, Yang, Yue, Fang, Jian
Publicado 2023

Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma

por Wang, Yang, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Tian, Guangming, Han, Sen, Long, Jieran, Zhang, Ziran, Fang, Jian
Publicado 2018

Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis

por Wang, Yang, Nie, Jun, Dai, Ling, Hu, Weiheng, Han, Sen, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Zhang, Ziran, Long, Jieran, Fang, Jian
Publicado 2023

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics

por Zhang, Jie, Gao, Jing, Li, Yanyan, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Shen, Lin, Fang, Jian
Publicado 2015

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer

por Hu, Weiheng, Fang, Jian, Nie, Jun, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Han, Sen, Han, Jindi, Wang, Yang, Long, Jieran
Publicado 2016

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

por Zhang, Jie, Wu, Di, Zhang, Ziran, Long, Jieran, Tian, Guangming, Wang, Yang, Ma, Xiangjuan, Chen, Xiaoling, Han, Jindi, Hu, Weiheng, Dai, Ling, Nie, Jun, Fang, Jian
Publicado 2021

Salvage treatment with anlotinib for advanced non‐small cell lung cancer

por Wu, Di, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Publicado 2019

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

por Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Publicado 2020

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

por Chen, Xiaoling, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Han, Jindi, Ma, Xiangjuan, Tian, Guangming, Han, Sen, Wu, Di, Wang, Yang, Long, Jieran, Zhang, Ziran, Fang, Jian
Publicado 2021

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients

por Ma, Xiangjuan, Zhang, Ziran, Chen, Xiaoling, Zhang, Jie, Nie, Jun, Da, Ling, Hu, Weiheng, Tian, Guangming, Wu, Di, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Fang, Jian
Publicado 2021

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

por Wang, Yang, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Wu, Di, Long, Jieran, Zhang, Ziran, Fang, Jian
Publicado 2021

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies

por Tian, Guangming, Zhao, Xinliang, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Wu, Di, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Publicado 2022

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

por Wang, Yang, Zhang, Xuanye, Tian, Dan, Han, Sen, Zhang, Jie, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Zhang, Ziran, Long, Jieran, Fang, Jian
Publicado 2022

Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer

por Zhang, Jie, Tian, Chen, Lv, Fang, Wang, Jianfei, Han, Wenbo, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Wu, Di, Han, Sen, Wang, Yang, Long, Jieran, Zhang, Ziran, Fang, Jian, Zhang, Henghui
Publicado 2019

放Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectr...

por Jia, Bo, Zhao, Xinghui, Wu, Di, Dong, Zhi, Chi, Yujia, Zhao, Jun, Wu, Meina, An, Tongtong, Wang, Yuyan, Zhuo, Minglei, Li, Jianjie, Chen, Xiaoling, Tian, Guangming, Long, Jieran, Yang, Xue, Chen, Hanxiao, Wang, Jingjing, Zhai, Xiaoyu, Li, Sheng, Li, Junfeng, Ma, Menglei, He, Yuling, Kong, Lingdong, Brcic, Luka, Fang, Jian, Wang, Ziping
Publicado 2021

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observ...

por Liang, Hongge, Song, Xia, Zhang, Yuhui, Zhang, Shucai, Li, Fang, Fang, Jian, Li, Junling, Liang, Li, Nie, Ligong, Ma, Kewei, Zhang, Liangming, Wang, Xiaohong, Xu, Junjun, Wei, Yanxia, Wang, Jinghui, Song, Qi, Tian, Guangming, Mu, Yuxin, Gu, Yangchun, Yang, Lei, Sun, Ping, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Wang, Mengzhao
Publicado 2019